Evidence map›Paper›PMID 36033384›Full record

ArticleJournal of immunology research2022

Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors.

Rui Huang, Yanfen Zheng, Wenxue Zou, Chao Liu, Jibing Liu, Jinbo Yue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui HuangDepartment of Graduate, Shandong Cancer Hospital and Institute, Shandong First Medical, University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Yanfen ZhengDepartment of Graduate, Shandong Cancer Hospital and Institute, Shandong First Medical, University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Wenxue ZouDepartment of Graduate, Shandong Cancer Hospital and Institute, Shandong First Medical, University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Chao LiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong, First Medical University and Shandong Academy of Medical Sciences, Jinan Shandong, China.
Jibing LiuDepartment of Interventional Radiology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.ORCID https://orcid.org/0000-0002-3674-1447
Jinbo YueDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong, First Medical University and Shandong Academy of Medical Sciences, Jinan Shandong, China.ORCID https://orcid.org/0000-0002-5768-8622

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the prognostic value of blood markers in patients with hepatitis B virus (HBV)-induced hepatocellular carcinoma (HCC) treated with PD-1 inhibitors. Results: The mean OS and PFS were 6.5 and 5.5 months, respectively. According to Kaplan-Meier survival curves, elevated systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) correlated with decreased OS and PFS (all Conclusion: SII, PLR, and PVTT predicted OS and PFS in HCC patients who received PD-1 inhibitors and, therefore, could be useful predictors for risk stratification and individualized therapeutic decision-making for patients with HBV-induced HCC treated with PD-1 inhibitors.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkersHepatitis B virusHumansImmune Checkpoint InhibitorsInflammationLymphocytesNeutrophilsPrognosisRetrospective StudiesBiomarkersImmune Checkpoint Inhibitors

Identifiers

PMID36033384
PMCPMC9402369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.